Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent nuclear threats [1][3][5] Collaboration Agreement - The collaboration will last for an initial three years, with the possibility of a three-year extension, focusing on stockpiling and distribution of PLX-R18 [1][2] - Pluri will produce PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9] Strategic Goals - The collaboration aims to secure external funding to establish an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5] - Hemafund will manage the storage and logistics of PLX-R18, ensuring rapid deployment in emergencies [4][9] Financial Implications - If successful, the collaboration could generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5][8] Context and Urgency - The collaboration is a proactive response to recent escalations in nuclear threats, highlighting the urgent need for effective radiation countermeasures in Ukraine [3][10] Company Background - Hemafund specializes in the preservation of umbilical cord blood and operates advanced cryostorage facilities in Ukraine [11] - Pluri is focused on developing cell-based products and solutions across various sectors, including regenerative medicine and food technology [12]

Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent escalations in regional nuclear threats [1][3]. Group 1: Collaboration Agreement - The collaboration agreement is effective for an initial period of three years, with the possibility of a three-year extension [1]. - Pluri will produce and supply PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9]. - The collaboration aims to secure external funding to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5]. Group 2: Strategic Goals - The collaboration addresses Ukraine's urgent need for radiation countermeasures and ensures secure storage and rapid deployment of treatments [8]. - It seeks to attract public and private funding to support the development and accessibility of PLX-R18 [9]. - The collaboration may potentially generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5]. Group 3: Context and Need - The collaboration is a response to recent incidents, including a Russian drone strike on the Chernobyl nuclear power plant, highlighting the need for effective radiation countermeasures [3]. - H-ARS is caused by exposure to high levels of ionizing radiation, leading to severe health risks [6].